tiprankstipranks
Ocular Therapeutix Inc (CH:0OT)
NASDAQ:0OT
Switzerland Market
0OT
Ocular Therapeutix
RESEARCH TOOLSreports

Ocular Therapeutix (0OT) Earnings Dates, Call Summary & Reports

0 Followers

Earnings Data

Report Date
Aug 10, 2026
After Close (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
-0.32
Last Year’s EPS
-0.31
Same Quarter Last Year
Analyst Consensus
Strong Buy
Based on 9 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 04, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and financial stability, with strong support from payers and successful trial execution. However, challenges such as market pricing pressure and potential enrollment difficulties in diabetic retinopathy trials were noted.
Company Guidance
During the Ocular Therapeutix Third Quarter 2025 Earnings Conference Call, the company provided extensive guidance on its ongoing and future clinical trials, emphasizing the transformative potential of their drug AXPAXLI (OTX-TKI) for wet age-related macular degeneration (AMD) and diabetic retinopathy. Key metrics included the successful randomization of 555 subjects in the SOL-R trial, anticipated top line data from the SOL-1 trial in Q1 2026, and the planned HELIOS program, which aims to secure a broad label for diabetic retinopathy and diabetic macular edema (DME). The company highlighted its strategic triad of potential superiority labeling, market expansion, and immediate adaptability, supported by a robust cash position of $345 million at the end of Q3 2025, supplemented by $445 million from a recent financing. These initiatives aim to redefine the retina market by addressing the $15 billion global anti-VEGF sector's unmet needs and improving patient adherence and treatment outcomes.
SOL-R Reaches Target Randomization
SOL-R has reached its target randomization of 555 subjects, marking a significant milestone and reflecting exceptional execution and investigator enthusiasm.
Financial Strength
Ocular ended Q3 2025 with approximately $345 million in cash, not including $445 million in net proceeds from an October equity financing, providing a cash runway into 2028.
Potential Superiority Label
AXPAXLI is expected to be the first and only therapy with a superiority label in wet AMD compared to a single dose of anti-VEGF, which could change market dynamics.
HELIOS Program Launch
The HELIOS program for diabetic retinopathy aims to capture the entire spectrum of diabetic retinal disease through superiority trials HELIOS-2 and HELIOS-3.
Positive Feedback From Payers
Payers have expressed enthusiasm about AXPAXLI's potential durability and clinical differentiation, indicating strong market support.

Ocular Therapeutix (CH:0OT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

CH:0OT Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 10, 2026
2026 (Q2)
-0.32 / -
-0.314―――
May 05, 2026
2026 (Q1)
-0.25 / -0.32
-0.306-5.26% (-0.02)―
Feb 05, 2026
2025 (Q4)
-0.26 / -0.23
-0.2330.00% (0.00)――
Nov 04, 2025
2025 (Q3)
-0.30 / -0.31
-0.177-72.73% (-0.13)―
Aug 05, 2025
2025 (Q2)
-0.29 / -0.31
-0.209-50.00% (-0.10)―
May 05, 2025
2025 (Q1)
-0.24 / -0.31
-0.39422.45% (+0.09)――
Mar 03, 2025
2024 (Q4)
-0.20 / -0.23
-0.28217.14% (+0.05)―
Nov 14, 2024
2024 (Q3)
-0.20 / -0.18
-0.005-3566.67% (-0.17)―
Aug 07, 2024
2024 (Q2)
-0.18 / -0.21
-0.2090.00% (0.00)―
May 07, 2024
2024 (Q1)
-0.15 / -0.39
-0.314-25.64% (-0.08)――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

FAQ

When does Ocular Therapeutix Inc (CH:0OT) report earnings?
Ocular Therapeutix Inc (CH:0OT) is schdueled to report earning on Aug 10, 2026, After Close (Confirmed).
    What is Ocular Therapeutix Inc (CH:0OT) earnings time?
    Ocular Therapeutix Inc (CH:0OT) earnings time is at Aug 10, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Ocular Therapeutix Inc stock?
          The P/E ratio of Ocular Therapeutix is N/A.
            What is CH:0OT EPS forecast?
            CH:0OT EPS forecast for the fiscal quarter 2026 (Q2) is -0.32.